Awaiting FDA hold letter, PepGen accepts 2nd oligonucleotide is no closer to clinic

PepGen has bowed to the inevitable and paused plans to get its second oligonucleotide therapy into the clinic in any country while it continues to wait for the post to deliver an FDA clinical hold letter.